Can Hypothyroidism Cause Fetal Demise?
Yes, maternal hypothyroidism significantly increases the risk of fetal demise, including both miscarriage and stillbirth, with the risk escalating as thyroid dysfunction severity increases.
Evidence for the Association
The 2012 Endocrine Society Clinical Practice Guidelines clearly establish that untreated thyroid dysfunction, particularly hypothyroidism, results in serious pregnancy complications including early pregnancy loss 1. The guidelines emphasize that optimal treatment of maternal overt hypothyroidism prevents these complications.
Quantified Risk Data
The relationship between maternal TSH levels and fetal loss is dose-dependent:
For every doubling of TSH concentration, the risk of child loss (miscarriage, fetal or neonatal death) increases by 60-80% (adjusted OR 1.80,95% CI: 1.07-3.03), even in women without overt thyroid dysfunction 2.
Women with TSH >10 mIU/L face approximately double the risk of spontaneous abortion (12.5% vs 6.5%, aOR 2.0,95% CI: 0.8-5.2) compared to euthyroid women 3.
Pregnancies with impaired thyroid function show significantly elevated TSH (median 1.133 vs 1.007 MoM) and decreased free T4 (median 0.958 vs 0.992 MoM) in cases ending in fetal loss 4.
Severity Stratification
Overt Hypothyroidism
This carries the highest and most clearly established risk for fetal demise 1, 5. The mechanism appears to involve uteroplacental ischemia and placental abruption, as demonstrated by case reports showing multifocal hemorrhagic infarctions and abruptions in placentas from women with inadequately treated hypothyroidism 6.
Subclinical Hypothyroidism
The guidelines acknowledge that subclinical hypothyroidism (TSH 2.5-5.0 mIU/liter in first trimester) is associated with increased early pregnancy loss, placental abruption, and other adverse outcomes 1. However, some studies show contradictory results, with the most recent large cohort (2023) showing no significant increase in adverse outcomes when TSH is between 6.0-10 mIU/L 3.
Critical Clinical Implications
The key protective factor is early detection and adequate treatment. The evidence demonstrates that:
Correction of hypothyroidism before pregnancy restores pregnancy outcomes to rates seen in euthyroid women 1.
Meticulous monitoring and normalization of thyroid function by the end of first trimester/early second trimester can prevent stillbirth, even in women with history of recurrent pregnancy loss 6.
Treatment initiated at 12 weeks or later may be too late to prevent all adverse outcomes 1.
Important Caveats
Thyroid autoantibody positivity alone (without TSH elevation) does not appear to independently increase fetal loss risk 3. The 2023 study found no association between TPO-Ab or Tg-Ab positivity and spontaneous abortion or preterm birth when TSH was normal.
The threshold for concern is TSH >10 mIU/L, where adverse outcomes become more pronounced 3. However, even modest TSH elevations (>2.5 mIU/L in first trimester) warrant treatment consideration given the dose-dependent relationship 1, 2.
Clinical Action Points
- Screen high-risk women early in pregnancy (ideally preconception)
- Treat overt hypothyroidism immediately with levothyroxine
- Consider treatment for subclinical hypothyroidism, especially with TSH >2.5 mIU/L in first trimester
- Target normalization of thyroid function by end of first trimester
- Monitor TSH every 4 weeks during pregnancy in treated women
- Do not delay treatment waiting for repeat testing when TSH is significantly elevated (>10 mIU/L)
The evidence strongly supports that untreated maternal hypothyroidism is a modifiable risk factor for fetal demise, and appropriate levothyroxine therapy substantially reduces this risk 1, 6.